Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus

Molecular Immunology

Volumn 52, Issue 2, 2012, Pages 61-70

  Yuan, Yao ^a   Kasar, Siddha ^a   Underbayev, Chingiz ^a   Vollenweider, Daniel ^a   Salerno, Erica ^a   Kotenko, Sergei V ^a   Raveche, Elizabeth ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoantibodies; Interferons; MicroRNA; NZB NZW F1

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; INTERFERON; INTERLEUKIN 10; LAMBDA INTERFERON; MICRORNA 15A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; GENE EXPRESSION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; INTERFERON-ALPHA; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; MICRORNAS; RECOMBINANT PROTEINS; SPLEEN; UP-REGULATION;

MURINAE; MUS;

EID: 84861685780     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.04.007     Document Type: Article

References (73)

1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. New England Journal of Medicine 2008, 358:929-939.
2. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine 2003, 349:1526-1533.
3. Auborn K.J., Qi M., Yan X.J., Teichberg S., Chen D., Madaio M.P., et al. Lifespan is prolonged in autoimmune-prone (NZB/NZW)F1 mice fed a diet supplemented with indole-3-carbinol. Journal of Nutrition 2003, 133:3610-3613.
4. Gualtierotti R., Biggioggero M., Penatti A.E., Meroni P.L. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmunity Reviews 2010, 10:3-7.
5. Anolik J.H., Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Practice and Research. Clinical Rheumatology 2005, 19:859-878.
6. Singh R.R., Hahn B.H. Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunological Reviews 1998, 164:201-208.
7. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Advances in Immunology 1985, 37:269-390.
8. Monneaux F., Dumortier H., Steiner G., Briand J.P., Muller S. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB×NZW)F(1) lupus mice. International Immunology 2001, 13:1155-1163.
9. Wofsy D., Chiang N.Y. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB×NZW)F1 mice. European Journal of Immunology 1987, 17:809-814.
10. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis and Rheumatism 2009, 60:1785-1796.
11. Kong CUoH. 2008. Can Targeted Elimination of B-Cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus. http://clinicaltrials.gov/.
12. Weckerle C.E., Franek B.S., Kelly J.A., Kumabe M., Mikolaitis R.A., Green S.L., et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis and Rheumatism 2011, 63:1044-1053.
13. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black×New Zealand White) F1 but not in BALB/c mice. Journal of Immunology 2005, 174:2499-2506.
14. Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clinical Rheumatology 2005, 24:178-181.
15. Ho V., McLean A., Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 2008, 14:166-168.
16. Kotenko S.V. IFN-lambdas. Current Opinion in Immunology 2011, 23:583-590.
17. Stoltz M., Klingstrom J. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. Journal of Virology 2010, 84:9140-9148.
18. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. Journal of Interferon and Cytokine Research 2010, 30:555-564.
19. Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last!. Nature Reviews Rheumatology 2011, 7:255-256.
20. Chen H., Zheng W., Su J., Xu D., Wang Q., Leng X., et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus - a prospective pilot study. Rheumatology 2011, 50:1640-1644.
21. Haas K.M., Watanabe R., Matsushita T., Nakashima H., Ishiura N., Okochi H., et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. Journal of Immunology 2010, 184:4789-4800.
22. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
23. Watanabe R., Ishiura N., Nakashima H., Kuwano Y., Okochi H., Tamaki K., et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. Journal of Immunology 2010, 184:4801-4809.
24. Blair P.A., Chavez-Rueda K.A., Evans J.G., Shlomchik M.J., Eddaoudi A., Isenberg D.A., et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. Journal of Immunology 2009, 182:3492-3502.
25. Matsushita T., Horikawa M., Iwata Y., Regulatory Tedder T.F. B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. Journal of Immunology 2010, 185:2240-2252.
26. Chan E.K., Satoh M., Pauley K.M. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need?. Arthritis and Rheumatism 2009, 60:912-915.
27. Pauley K.M., Cha S., Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. Journal of Autoimmunity 2009, 32:189-194.
28. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmunity Reviews 2009, 8:520-524.
29. Belver L., de Yebenes V.G., Ramiro A.R. MicroRNAs prevent the generation of autoreactive antibodies. Immunity 2010, 33:713-722.
30. Bluml S., Bonelli M., Niederreiter B., Puchner A., Mayr G., Hayer S., et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis and Rheumatism 2011, 63:1281-1288.
31. Dai R., Zhang Y., Khan D., Heid B., Caudell D., Crasta O., et al. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One 2010, 5:e14302.
32. Dai Y., Huang Y.S., Tang M., Lv T.Y., Hu C.X., Tan Y.H., et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007, 16:939-946.
33. Thai T.H., Christiansen P.A., Tsokos G.C. Is there a link between dysregulated miRNA expression and disease?. Discovery Medicine 2010, 10:184-194.
34. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nature Reviews Cancer 2006, 6:259-269.
35. Rigby R.J., Vinuesa C.G. SiLEncing SLE: the power and promise of small noncoding RNAs. Current Opinion in Rheumatology 2008, 20:526-531.
36. Tili E., Michaille J.J., Costinean S., Croce C.M. MicroRNAs, the immune system and rheumatic disease. Nature Clinical Practice Rheumatology 2008, 4:534-541.
37. Kopreski M.S., Benko F.A., Gocke C.D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Annals of the New York Academy of Sciences 2001, 945:172-178.
38. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10513-10518.
39. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opinion on Biological Therapy 2009, 9:703-711.
40. Caby M.P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C. Exosomal-like vesicles are present in human blood plasma. International Immunology 2005, 17:879-887.
41. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 2007, 9:654-659.
42. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.R., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. Journal of Immunology 2000, 165:5970-5979.
43. Starke C., Frey S., Wellmann U., Urbonaviciute V., Herrmann M., Amann K., et al. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. European Journal of Immunology 2011, 41:2107-2112.
44. Giordani L., Sanchez M., Libri I., Quaranta M.G., Mattioli B., Viora M. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. Journal of Leukocyte Biology 2009, 86:261-271.
45. Mathian A., Gallegos M., Pascual V., Banchereau J., Koutouzov S. Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice. European Journal of Immunology 2011, 41:863-872.
46. Cobaleda C., Schebesta A., Delogu A., Busslinger M. Pax5: the guardian of B cell identity and function. Nature Immunology 2007, 8:463-470.
47. Chung E.Y., Dews M., Cozma D., Yu D., Wentzel E.A., Chang T.C., et al. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biology and Therapy 2008, 7:1758-1764.
48. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation 2008, 118:3420-3430.
49. Raveche E.S., Salerno E., Scaglione B.J., Manohar V., Abbasi F., Lin Y.C., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007, 109:5079-5086.
50. Rossi R.L., Rossetti G., Wenandy L., Curti S., Ripamonti A., Bonnal R.J., et al. Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nature Immunology 2011, 12:796-803.
51. Abushahba W., Balan M., Castaneda I., Yuan Y., Reuhl K., Raveche E., et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunology, Immunotherapy 2010, 59:1059-1071.
52. Hong S.H., Cho O., Kim K., Shin H.J., Kotenko S.V., Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Research 2007, 126:245-249.
53. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Research 2006, 66:4468-4477.
54. Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. Journal of General Virology 2005, 86:1589-1596.
55. Zimmerer J.M., Lesinski G.B., Ruppert A.S., Radmacher M.D., Noble C., Kendra K., et al. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clinical Cancer Research 2008, 14:5900-5906.
56. Rani M.R., Shrock J., Appachi S., Rudick R.A., Williams B.R., Ransohoff R.M. Novel interferon-beta-induced gene expression in peripheral blood cells. Journal of Leukocyte Biology 2007, 82:1353-1360.
57. Tomokuni A., Eguchi H., Tomimaru Y., Wada H., Kawamoto K., Kobayashi S., et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications 2011, 414:675-680.
58. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
59. Scagnolari C., Zingariello P., Vecchiet J., Selvaggi C., Racciatti D., Taliani G., et al. Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virology Journal 2010, 7:311.
60. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. New England Journal of Medicine 2009, 361:1437-1447.
61. Grigoryev Y.A., Kurian S.M., Hart T., Nakorchevsky A.A., Chen C., Campbell D., et al. MicroRNA regulation of molecular networks mapped by global microRNA, mRNA, and protein expression in activated T lymphocytes. Journal of Immunology 2011, 187:2233-2243.
62. Salerno E., Scaglione B.J., Coffman F.D., Brown B.D., Baccarini A., Fernandes H., et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Molecular Cancer Therapeutics 2009, 8:2684-2692.
63. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:13944-13949.
64. Kasar S., Salerno E., Yuan Y., Underbayev C., Vollenweider D., Laurindo M.F.et al. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes and Immunity 2011.
65. Pauley K.M., Satoh M., Chan A.L., Bubb M.R., Reeves W.H., Chan E.K. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Research and Therapy 2008, 10:R101.
66. Nagata Y., Nakasa T., Mochizuki Y., Ishikawa M., Miyaki S., Shibuya H., et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis and Rheumatism 2009, 60:2677-2683.
67. Murray P.J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:8686-8691.
68. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. Journal of Immunology 2009, 182:7459-7472.
69. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nature Reviews Immunology 2010, 10:236-247.
70. Sekigawa I., Ishida Y., Hirose S., Sato H., Shirai T. Cellular basis of in vitro anti-DNA antibody production: evidence for T cell dependence of IgG-class anti-DNA antibody synthesis in the (NZB×NZW)F1 hybrid. Journal of Immunology 1986, 136:1247-1252.
71. Ando D.G., Sercarz E.E., Hahn B.H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. Journal of Immunology 1987, 138:3185-3190.
72. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. Journal of Immunology 2005, 174:4389-4399.
73. Calin G.A., Croce C.M. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Seminars in Oncology 2006, 33:167-173.